Table 2.
Comparison of demographic and clinical features in SLE patients with and without AP.
| SLE with AP (n = 27) | SLE without AP (n = 23) | P | |
|---|---|---|---|
| Female (%) | 25 (92.59%) | 20 (86.96%) | 0.42 |
| Age on SLE diagnosis (y) | 26.96 ± 13.30 | 28.39 ± 9.98 | 0.26 |
| GCs dose (mg) | 61.19 ± 37.63 | 50.96 ± 28.82 | 0.18 |
| SLEDAI score | 21.70 ± 10.32 | 16.17 ± 7.51 | 0.03 |
| SLICC/ACR damage index | 1.19 ± 0.92 | 0.96 ± 1.19 | 0.11 |
| Mortality | 10 (37.04%) | 0 | 0.001 |
| Fever (%) | 21 (77.78%) | 9 (39.13%) | 0.006 |
| Neuropsychiatric (%) | 7 (25.93%) | 1 (4.35%) | 0.042 |
| Pulmonary (%) | 11 (40.74%) | 5 (21.74%) | 0.13 |
| Articular (%) | 16 (59.26%) | 16 (69.57%) | 0.32 |
| Mucocutaneous involvement (%) | 18 (66.67%) | 16 (69.57%) | 0.54 |
| Renal (%) | 24 (88.89%) | 20 (86.96%) | 0.59 |
| Hepatological (%) | 19 (82.61%) | 8 (34.78%) | 0.01 |
| Hematological (%) | 27 (100.00%) | 14 (60.87%) | 0.001 |
| Serositis (%) | 17 (62.96%) | 6 (26.09%) | 0.01 |
| Number of organs involved | 5.70 ± 1.56 | 3.96 ± 1.15 | 0.001 |
| Positive anti-dsDNA (%) | 24 (88.89%) | 19 (82.61%) | 0.41 |
| Positive anti-Sm (%) | 6/21 (28.57%) | 10 (43.48%) | 0.24 |
| Positive anti-Ro (%) | 13/21 (61.90%) | 14 (60.87%) | 0.60 |
| Positive anti-La (%) | 7/21 (33.33%) | 0 | 0.003 |
| Positive ACL-IgG (%) | 4/21 (19.05%) | 1/22 (4.55%) | 0.168 |
| Positive ACL-IgM (%) | 4/21 (19.05%) | 1/22 (4.55%) | 0.16 |
| Positive anti-β 2 GPI (%) | 3/21 (14.29%) | 2/22 (9.09%) | 0.48 |
| Low C3 (%) | 26/26 (100%) | 22 (95.65%) | 0.47 |
| Low C4 (%) | 21/26 (80.77%) | 20 (86.96%) | 0.42 |
| Elevated CRP (%) | 18/22 (81.82%) | 10/21 (47.62%) | 0.02 |